Key result
Riociguat lowers pulmonary vascular resistance index by ~45% in acute pulmonary hypertension.
Why the study?
Although riociguat may be effective in treating dogs with refractory pulmonary hypertension, basic studies on its clinical application in veterinary medicine are lacking.
Does riociguat reduce pulmonary artery pressure and vascular resistance in a canine model of acute pulmonary hypertension?
Does riociguat reduce pulmonary artery pressure and vascular resistance in a canine model of acute pulmonary hypertension?
Riociguat effectively attenuates pulmonary vascular resistance and pulmonary artery pressure without compromising basal systemic arterial pressure in a canine model of acute pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for riociguat in acute pulmonary hypertension; human trials needed before clinical consideration.
Soluble guanylate cyclase (sGC) stimulator riociguat is a relatively novel therapeutic agent for pulmonary hypertension (PH) in human medicine. Riociguat induces endothelium-independent pulmonary artery (PA) relaxation by directly activating the sGC-cyclic guanosine-3',5'-monophosphate (cGMP) pathway in muscle cells. Although riociguat may be effective in the treatment of dogs with refractory PH, basic studies on its clinical application in veterinary medicine are lacking. The present study aimed to explore the effects of riociguat on the contractility of an isolated canine PA and the hemodynamics of dogs with acute PH. In an isolated endothelium-denuded canine PA, the effects of riociguat on endothelin (ET)-1-induced contraction and cGMP levels were investigated using the Magnus method and ELISA, respectively. The effect of riociguat on the hemodynamics of the thromboxane A2 analog U46619-induced PH model dog was examined by invasive catheterization. Riociguat increased cGMP levels and reduced ET-1-induced contraction of the isolated PA. Riociguat inhibited the U46619-induced elevation of PA pressure and pulmonary vascular resistance and increased cardiac output, but it had no effect on basal systemic blood pressure. These results demonstrate for the first time that riociguat can inhibit the elevation of PA pressure through PA relaxation via an endothelium-independent increase in cGMP in dogs with PH.
No takes yet. Share an insight, caveat, or question.
Kameshima et al. (2023) studied Acute pulmonary hypertension (n=8). Riociguat vs. U46619 alone (control) was evaluated on Pulmonary vascular resistance (PVR) index under U46619 administration (p=<0.05). Riociguat significantly inhibited the U46619-induced elevation of pulmonary vascular resistance and pulmonary artery pressure while increasing cardiac output in dogs with acute pulmonary hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: